You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

CLINICAL TRIALS PROFILE FOR CORTROSYN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cortrosyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00462644 ↗ Evaluation of Etomidate on Adrenal Function in Trauma Patients Completed University of Tennessee N/A 2006-02-01 Trauma patients are at increased risk for adrenal function insufficiency. A commonly used agent for rapid sequence intubation (RSI) is known to decrease adrenal function. We want to determine the incidence of adrenocortical insufficiency and its significance during the first 24 hours of resuscitation following RSI in trauma patients.
NCT00484679 ↗ Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Completed National Alopecia Areata Foundation Phase 2 2007-05-01 The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
NCT00484679 ↗ Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Completed University of Minnesota Phase 2 2007-05-01 The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
NCT00484679 ↗ Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 2007-05-01 The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cortrosyn

Condition Name

Condition Name for Cortrosyn
Intervention Trials
Sepsis 1
Stress 1
Adrenal Insufficiency 1
Alopecia Areata 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cortrosyn
Intervention Trials
Alopecia Areata 1
Night Blindness 1
Alopecia 1
Tachycardia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cortrosyn

Trials by Country

Trials by Country for Cortrosyn
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cortrosyn
Location Trials
Virginia 2
Tennessee 2
Michigan 1
Washington 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cortrosyn

Clinical Trial Phase

Clinical Trial Phase for Cortrosyn
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cortrosyn
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cortrosyn

Sponsor Name

Sponsor Name for Cortrosyn
Sponsor Trials
University of Virginia 1
University of Michigan 1
National Heart, Lung, and Blood Institute (NHLBI) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cortrosyn
Sponsor Trials
Other 10
NIH 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Corcept Therapeutics' Drugs, Including Relacorilant and Korlym

Introduction to Corcept Therapeutics and Its Focus

Corcept Therapeutics is a pharmaceutical company specializing in drugs that modulate the effects of cortisol, a hormone crucial for various bodily functions but potentially harmful in excess. The company's primary focus is on treating conditions such as Cushing’s syndrome, a disorder caused by excessive cortisol levels.

Clinical Trials Update

Relacorilant for Cushing’s Syndrome

Corcept Therapeutics has made significant progress in its clinical trials for relacorilant, a drug aimed at treating Cushing’s syndrome.

  • Phase 3 GRACE Trial: The pivotal Phase 3 GRACE trial has met its primary endpoint, demonstrating that patients treated with relacorilant experienced clinically meaningful improvements in hypertension, hyperglycemia, and other symptoms associated with hypercortisolism. The randomized withdrawal phase showed that patients who remained on relacorilant maintained these improvements, while those who received placebo saw a significant worsening of their symptoms[1][2].

  • Phase 3 GRADIENT Trial: The GRADIENT trial, another Phase 3 study, supported the findings of the GRACE trial. This trial involved 137 patients with Cushing’s syndrome caused by adrenal gland pathology and showed that relacorilant was well-tolerated and effective in improving a broad range of hypercortisolism signs and symptoms. There were no cases of relacorilant-induced hypokalemia, endometrial hypertrophy, vaginal bleeding, adrenal insufficiency, or QT prolongation[1].

Korlym and Other Clinical Trials

  • Korlym (Mifepristone): Korlym, Corcept's main product, is already FDA-approved for treating Cushing’s syndrome. During the third quarter of 2024, the company saw a significant increase in Korlym prescriptions and patient treatments, contributing to a 48% year-over-year revenue growth[1][2].

  • CATALYST Trial: The CATALYST trial is a prospective Phase 4 study assessing the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. The study has enrolled 1,055 patients and demonstrated a hypercortisolism prevalence rate of 24% in this population. The treatment phase results, comparing Korlym to placebo, are expected by the end of the year[4].

Market Analysis

Revenue and Financial Performance

Corcept Therapeutics has shown robust financial performance in 2024. Here are some key highlights:

  • Revenue Growth: The company reported revenue of $182.5 million in the third quarter of 2024, a 48% increase over the same period in 2023. This growth is largely attributed to the increased adoption of Korlym[1][2].

  • Revenue Guidance: Corcept has raised its full-year revenue guidance for 2024 to $675–$700 million, up from the previous range of $640–$670 million[1][2].

  • Net Income: The net income per common share (diluted) was $0.41 in the third quarter of 2024, compared to $0.28 in the third quarter of 2023[1].

Market Potential and Analyst Outlook

  • Analyst Upside Potential: Analysts have indicated a significant upside potential for Corcept Therapeutics, with some estimates suggesting a 47.86% potential increase. This optimism is driven by the positive results from clinical trials and the anticipated FDA approval for relacorilant[2].

  • Growth Runway: The potential approval of relacorilant and its possible extension into other indications are seen as key factors in Corcept's attractive growth runway. ClearBridge Small Cap Value Strategy has highlighted the efficacy and safety of relacorilant as significant positives for the company's future performance[2].

Market Projections

Cortisol Modulation Market

The market for cortisol modulation and related treatments is growing due to increasing awareness and diagnosis of hypercortisolism.

  • Cushing’s Syndrome Market: The success of Korlym and the impending approval of relacorilant position Corcept Therapeutics to dominate the Cushing’s syndrome treatment market. The rising awareness among physicians about hypercortisolism is leading to more screenings and treatments, which is critical for expanding the market[1][2].

  • Global Cortisone Market: While not directly related to Corcept's specific drugs, the global cortisone market provides context for the broader demand for cortisol-related treatments. The global cortisone market is expected to see continued growth, driven by increasing diagnoses and treatments of related conditions[5].

Other Indications and Future Directions

Early-Stage Prostate Cancer and ALS

Corcept Therapeutics is also exploring other therapeutic areas:

  • Early-Stage Prostate Cancer: Enrollment continues in a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with early-stage prostate cancer, conducted in collaboration with the University of Chicago[1].

  • Amyotrophic Lateral Sclerosis (ALS): The company has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in 249 patients with ALS, with results expected this quarter[1].

Key Takeaways

  • Clinical Success: Corcept Therapeutics has achieved significant clinical success with relacorilant in treating Cushing’s syndrome, supported by positive results from the GRACE and GRADIENT trials.
  • Financial Growth: The company has seen substantial revenue growth driven by increased adoption of Korlym and anticipates further growth with the potential approval of relacorilant.
  • Market Potential: Analysts predict a strong growth runway for Corcept Therapeutics, driven by the efficacy and safety of its drugs and potential extensions into other indications.
  • Expanding Therapeutic Areas: Corcept is exploring other therapeutic areas, including early-stage prostate cancer and ALS, which could further diversify its product portfolio.

FAQs

What is the current status of Corcept Therapeutics' relacorilant in clinical trials?

Relacorilant has shown positive results in Phase 3 trials (GRACE and GRADIENT) for treating Cushing’s syndrome and is expected to have its New Drug Application (NDA) submitted this quarter[1][2].

How has Korlym contributed to Corcept Therapeutics' revenue growth?

Korlym, Corcept's main product, has seen increased prescriptions and patient treatments, leading to a 48% year-over-year revenue growth in the third quarter of 2024[1][2].

What are the potential future indications for Corcept Therapeutics' drugs?

Besides Cushing’s syndrome, Corcept is exploring other indications such as early-stage prostate cancer and amyotrophic lateral sclerosis (ALS)[1].

What is the analyst outlook for Corcept Therapeutics' stock performance?

Analysts have indicated a significant upside potential for Corcept Therapeutics, with estimates suggesting a 47.86% potential increase, driven by positive clinical trial results and anticipated FDA approvals[2].

How does the global cortisone market impact Corcept Therapeutics' growth?

While the global cortisone market is not directly related to Corcept's specific drugs, it indicates a broader growing demand for cortisol-related treatments, which can positively impact Corcept's market position and growth potential[5].

Cited Sources

  1. Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update. Corcept Therapeutics. Retrieved October 30, 2024.
  2. 10 Stocks That Will Make You Rich In 2025. Insider Monkey. Retrieved December 24, 2024.
  3. CLINUVEL Adds ACTH to Portfolio. CLINUVEL. Retrieved November 8, 2021.
  4. Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions. Corcept Therapeutics. Retrieved June 24, 2024.
  5. Cortisone - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030. Market Research Reports. Retrieved September 27, 2024.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.